In order to further confirm that circHMGB2 can reshape the tumor immune microenvironment and limit the efficacy of anti-PD-1 in NSCLC, we performed in vivo experiments in mice with a humanized immune system. This evidence concerns the gene PDCD1 and neoplasm.